A comprehensive analysis of hypermutation in human cancer by the IRRDC has defined two subgroups of dMMR gliomas, with an average TMB of 380 mutation/MB and 80 mutation/MB according to the presence or absence of a secondary POLE mutation on top of the primary MMR mutation, respectively [59]. This evidence concerns the gene POLE and cancer.